Skip to main content
ZYBT logo

Zhengye Biotechnology Holding Limited (ZYBT) Stock Price & Analysis

Zhengye Biotechnology Holding Limited (ZYBT) — MoonshotScore 32/100 (Weak band), calculated Nov 18, 2026. Price $1.50 (-1.32%), as of the Nov 18, 2026 trading session; market cap $71.1M.

Educational signal · not a buy or sell recommendation · How to read this

$1.50 −$0.02 (-1.32%) Market Cap $71.1M

Zhengye Biotechnology Holding Limited · ZYBT · NASDAQ

Zhengye Biotechnology Holding Limited is a Chinese company focused on developing, manufacturing, and selling veterinary vaccines for livestock. They offer vaccines for a variety of animals and export to several countries.

Price as of Nov 18, 2026

Key Statistics

32 of 100

MoonshotScore v2 · Zhengye Biotechnology Holding (ZYBT)

Weak
Business Quality Thin (25)
Financial Safety Okay (52)
Valuation Full (49)
Growth Durability Shrinking (2)
Momentum Rising (66)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Weak quality, stalling growth and a full valuation, though the balance sheet is only middling. The score also carries a risk penalty for a bankruptcy-risk score in the grey zone and losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Okay; Valuation: Full; Growth Durability: Shrinking; Momentum: Rising.

  • quarterly revenue CN¥53M (Q4 FY2025, quarter ended Dec 31, 2025)
  • Altman Z 1.60 · Piotroski F 4
  • ROE -30.8% · ROA -18.8% · current ratio 1.14 · earnings yield -17.3% · free-cash-flow yield 5.3%

Holding back: weak fundamentals, soft growth

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for ZYBT (52 recorded, newest six shown)
RecordedScoreBand
31Weak
31Weak
31Weak
31Weak
32Weak
32Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$1.50
Change on the day-1.32%
Market capitalisation$71.1M—
Shares traded on the day22.2K

Price & events

Other perspectives

Council score for Zhengye Biotechnology Holding (ZYBT): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Weak
Financial Safety Neutral
Valuation Neutral
Growth Durability Negative
Momentum Moderate

Legends Council

3 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Unfavorable read

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Negative
Debt/Equity Neutral
ROE Negative
Gross Margin Negative

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Zhengye Biotechnology Holding (ZYBT), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Zhengye Biotechnology Holding Limited (ZYBT) is listed on NASDAQ. It employs 269 people. In Q4 FY2025 it reported revenue of CN¥53M and net income of -CN¥47M. The market values it at $71.1M.

2 · Latest results

What do the latest results show for Zhengye Biotechnology Holding (ZYBT)?

Short answer · as of

The most recent reported quarter, Q4 FY2025, carried revenue of CN¥53M.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q4 FY2025CN¥53M-CN¥47M-CN¥0.98 (diluted)
Q3 FY2025CN¥27M-CN¥24M-CN¥0.51 (diluted)
Q2 FY2025CN¥31M-CN¥11M-CN¥0.45 (diluted)
Q1 FY2025CN¥31M-CN¥11M-CN¥0.23 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Zhengye Biotechnology Holding (ZYBT)?

Short answer · as of

What is holding it back is weak fundamentals, soft growth. The distress and quality screens read Altman Z 1.60 · Piotroski F 4. Trailing ratios: ROE -30.8% · ROA -18.8% · current ratio 1.14 · earnings yield -17.3% · free-cash-flow yield 5.3%.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of 1.60 sits in the distress zone (elevated bankruptcy risk).
  • Negative return on equity (-30.8%) — the business is not currently generating profit on shareholder capital.
5 · Peer comparison

How does Zhengye Biotechnology Holding compare with its peers?

Short answer

Zhengye Biotechnology Holding's score ranks 7th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Cumberland Pharmaceuticals Inc. (CPIX) Same industry, near in market value$6.57 Nov 18, 2026$98.5M51 5-pillar Nov 18, 2026
Cardiol Therapeutics Inc. (CRDL) Same industry, near in market value$0.95 Nov 18, 2026$121M49 5-pillar Nov 18, 2026
Incannex Healthcare Limited (IXHL) Same industry, near in market value$1.75 Nov 18, 2026$22.0M48 5-pillar Nov 18, 2026
SIGA Technologies, Inc. (SIGA) Same industry, near in market value$2.80 Nov 18, 2026$201M38 5-pillar Nov 18, 2026
Organigram Global Inc. (OGI) Same industry, near in market value$0.68 Nov 18, 2026$95.5M35 5-pillar Nov 18, 2026
TherapeuticsMD, Inc. (TXMD) Same industry, near in market value$1.81 Nov 18, 2026$21.0M34 5-pillar Nov 18, 2026
Zhengye Biotechnology Holding (ZYBT) — this page$1.50$71.1M32
Journey Medical Corporation (DERM) Same industry, near in market value$3.69 Nov 18, 2026$104M31 5-pillar Nov 18, 2026
Talphera, Inc. (TLPH) Same industry, near in market value$0.80 Nov 18, 2026$41.6M31 5-pillar Nov 18, 2026
InterCure Ltd. (INCR) Same industry, near in market value$3.49 Nov 18, 2026$45.3M30 5-pillar Nov 18, 2026
Organogenesis Holdings Inc. (ORGO) Same industry, near in market value$0.85 Nov 18, 2026$111M28 5-pillar Nov 18, 2026
Aytu BioPharma, Inc. (AYTU) Same industry, near in market value$2.66 Nov 18, 2026$28.9M25 5-pillar Nov 18, 2026
Rockwell Medical, Inc. (RMTI) Same industry, near in market value$6.10 Nov 18, 2026$24.2M25 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held ZYBT in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported ZYBT in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Zhengye Biotechnology Holding (ZYBT)?

Read these with our analysis →

Zhengye Biotechnology Holding Stock: Key Questions Answered

These answers are editorial: 1 of these 9 answers is drawn from the ZYBT research dossier (written May 9, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for ZYBT?

ZYBT carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Zhengye Biotechnology Holding Limited is a Chinese company focused on developing, manufacturing, and selling veterinary vaccines for livestock.

Is ZYBT a good stock to buy?

Stock Expert AI does not rate ZYBT buy, sell or hold. Zhengye Biotechnology Holding Limited carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the ZYBT stock price today?

The last price recorded for Zhengye Biotechnology Holding Limited (ZYBT), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for ZYBT?

Zhengye Biotechnology Holding Limited faces several risks, including intense competition from established vaccine manufacturers, regulatory changes in China and export markets, and outbreaks of new animal diseases. Fluctuations in raw material costs and its negative profit margin also pose significant challenges. The company's small market capitalization and high beta further contribute to its risk profile.

What are the key factors to evaluate for ZYBT?

Zhengye Biotechnology Holding Limited (ZYBT) holds a MoonshotScore in the low range. The company's product portfolio includes vaccines for swine, cattle, goats, sheep, poultry, and dogs. Not financial advice.

How frequently does ZYBT data refresh on this page?

ZYBT's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven ZYBT's recent stock price performance?

Zhengye Biotechnology Holding Limited (ZYBT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized in veterinary vaccines for livestock. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider ZYBT overvalued or undervalued right now?

Zhengye Biotechnology Holding Limited (ZYBT) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of ZYBT?

Fractional-share availability for Zhengye Biotechnology Holding Limited (ZYBT) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 12 figures on this page — 8 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.